D-threo-2-Pentulose,1-C-[(2S,3S)-7-[[4-O-acetyl-2,6-dideoxy-3-O-(2,6-dideoxy-4-O-methyl-a-D-lyxo-hexopyranosyl)-b-D-lyxo-hexopyranosyl]oxy]-3-[[O-4-O-acetyl-2,6-dideoxy-3-C-methyl-a-L-arabino-hexopyranosyl-(1®3)-O-2,6-dideoxy-b-D-arabino-hexopyranosyl-(1®3)-2,6-dideoxy-b-D-arabino-hexopyranosyl]oxy]-1,2,3,4-tetrahydro-5,10-dihydroxy-6-methyl-4-oxo-2-anthracenyl]-5-deoxy-1-O-methyl-,(1S)- cas no:7059-24-7

NameD-threo-2-Pentulose,1-C-[(2S,3S)-7-[[4-O-acetyl-2,6-dideoxy-3-O-(2,6-dideoxy-4-O-methyl-a-D-lyxo-hexopyranosyl)-b-D-lyxo-hexopyranosyl]oxy]-3-[[O-4-O-acetyl-2,6-dideoxy-3-C-methyl-a-L-arabino-hexopyranosyl-(1®3)-O-2,6-dideoxy-b-D-arabino-hexopyranosyl-(1®3)-2,6-dideoxy-b-D-arabino-hexopyranosyl]oxy]-1,2,3,4-tetrahydro-5,10-dihydroxy-6-methyl-4-oxo-2-anthracenyl]-5-deoxy-1-O-methyl-,(1S)-
CAS7059-24-7
SynonymsChromomycinA3 (8CI); Olivomycin D, 3D-O-(4-O-acetyl-2,6-dideoxy-3-C-methyl-a-L-arabino-hexopyranosyl)-7-methyl-;Aburamycin B; Antibiotic B 599; CMA3; NSC 58514; Toyomycin
EINECS(EC#)230-348-0
Molecular FormulaC57H82 O26
Molecular Weight1183.39

refractive index1.608
storage temp2-8°C

Hazardclass6.1(a)

Hazard T+,T
Risk 61-28
Safety

A deadly poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. An experimental teratogen. Experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits acrid smoke and fumes.
Safty information about Chromomycin A3 (CAS NO.7059-24-7) :
Hazard Codes：
T+
T 
Risk Statements：
R61:May cause harm to the unborn child.  
R28:Very toxic if swallowed. 
Safety Statements:
S53:Avoid exposure - obtain special instructions before use. 
S28:After contact with skin, wash immediately with plenty of soap-suds. 
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection. 
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) 
RIDADR: UN 3462 6.1/PG 1
WGK Germany: 3
RTECS: GB7875000
F: 
F 3: Hygroscopic.
F 8: Photosensitive.
F 10: Keep under argon.
HazardClass: 6.1(a)
PackingGroup: I

1.		dnr-bcs 800 ng/plate		TAKHAA    Takeda Kenkyusho Ho. Journal of the Takeda Research Laboratories. 44 (1985),96.
2.		dnd-hmn:hla 400 µg/L		CNREA8    Cancer Research. 45 (1985),2813.
3.		msc-hmn:hla 8 µg/L		CNREA8    Cancer Research. 45 (1985),2813.
4.		msc-mus:emb 25 µg/L		CNREA8    Cancer Research. 45 (1985),2813.
5.		ipr-rat LDLo:250 µg/kg		85ERAY    Antibiotics: Origin, Nature, and Properties. 2 (1978),1401.
6.		orl-mus LD50:1431 µg/kg		NCISP*    National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program, Bethesda, MD 20205 JAN86 .
7.		ipr-mus LD50:800 µg/kg		JAJAAA    Journal of Antibiotics, Series A. 16 (1963),22.
8.		scu-mus LD50:2800 µg/kg		NIIRDN    “Drugs in Japan. Ethical Drugs, 6th Edition 1982“ Edited by Japan Pharmaceutical Information Center. 6 (1982),245.
9.		ivn-mus LD50:1 mg/kg		JAJAAA    Journal of Antibiotics, Series A. 16 (1963),22.
10.		ipr-dog LDLo:250 µg/kg		85ERAY